Table 3. Unadjusted and propensity-score adjusted hazard ratios for 1-year endpoint in patients with PPIs versus no-PPIs within each P2Y12 receptor inhibitors (clopidogrel or ticagrelor).

	Clopidogrel				Ticagrelor				P, Interaction of treatment with PPIs use, unadjusted/adjusted
	Treated with PPIs (n = 4814)	Not treated with PPIs (n = 4126)	Unadjusted HR (95% CI)	Adjusted HR (95% CI)	Treated with PPIs (n = 351)	Not treated with PPIs (n = 138)	Unadjusted HR (95% CI)	Adjusted HR (95% CI)
All-cause death/re-infarction bleeding	533/4814 (11.1%)	348/4126 (8.4%)	1.331 (1.161–1.524)	1.036 (0.903–1.189)	28/351 (8.0%)	5/138 (3.6%)	2.191 (0.846–5.674)	2.320 (0.875–6.151)	0.3100/0.2004
All-cause death/re-infarction	395/4814 (8.2%)	259/4126 (6.3%)	1.320 (1.129–1.544)	1.006 (0.858–1.181)	11/351 (3.1%)	1/138 (0.7%)	4.345 (0.561–33.658)	4.003 (0.502–31.932)	0.2534/0.2001
All-cause death	248/4814 (5.2%)	133/4126 (3.2%)	1.614 (1.307–1.992)	1.101 (0.889–1.364)	9/3519 (2.6%)	1/138 (0.7%)	3.536 (0.448–27.888)	3.199 (0.388–26.393)	0.4546/0.3608
Re-infarction	213/4814 (4.3%)	186/4126 (4.5%)	1.604 (1.299–1.980)	0.828 (0.677–1.012)	2/351 (0.6%)	0/138 (0.0%)	-	-	0.9679/0.9566
Bleeding	181/4814 (3.8%)	111/4126 (2.7%)	1.416 (1.118–1.794)	1.101 (0.865–1.401)	17/351 (4.8%)	5/138 (3.6%)	1.331 (0.491–3.607)	1.482 (0.533–4.117)	0.9028/0.9748

HR (unadjusted and adjusted) showing the relationship between PPIs and clinical outcomes. HR: hazard ratios; PPIs: proton pump inhibitors.